	US 12,421,526 B2
	AAV mutant having brain-targeting property
Toshikazu Nishie, Kusatsu (JP); Fuyuko Takashima, Kusatsu (JP); Tatsuji Enoki, Kusatsu (JP); Junichi Mineno, Kusatsu (JP); and Yoshinori Tanaka, Kusatsu (JP)
Assigned to TAKARA BIO INC., Shiga (JP)
Appl. No. 17/442,386
Filed by TAKARA BIO INC., Shiga (JP)
PCT Filed Apr. 23, 2020, PCT No. PCT/JP2020/017495 § 371(c)(1), (2) Date Sep. 23, 2021, PCT Pub. No. WO2020/218419, PCT Pub. Date Oct. 29, 2020.
Claims priority of application No. 2019-082417 (JP), filed on Apr. 24, 2019.
Prior Publication US 2022/0162637 A1, May 26, 2022
Int. Cl. C12N 15/86 (2006.01); C07K 14/015 (2006.01); C12N 7/00 (2006.01)

CPC C12N 15/86 (2013.01) [C07K 14/015 (2013.01); C12N 7/00 (2013.01); C12N 2710/10041 (2013.01)]

5 Claims

1. A nucleic acid encoding a mutant of an adeno-associated virus-2 (AAV-2) capsid protein comprising a peptide, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 66, and wherein the peptide is placed at a position between amino acids corresponding to amino acid number 588 and amino acid number 589 of AAV2 VP1 in the AAV capsid protein and wherein the mutant AAV-2 capsid protein has cellular tropism for the brain and/or lungs.